Brief: Pfizer Submitted Its Sweetened Bid To Buy Metsera, Which Matches Novo’S Offer Valuing Metsera At $86.20 A Share - FT
Nov 5 (Reuters) - PFIZER SUBMITTED ITS SWEETENED BID TO BUY METSERA, WHICH MATCHES NOVO’S OFFER VALUING METSERA AT $86.20 A SHARE - FT Source text: https://tinyurl.com/3a5ywse7 Further company coverage: MTSR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Metsera
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up